# US 2019/0316121 A1 · Modified Guide RNAs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316121 A1
- Document ID: US20190316121A1
- Status: Published application
- Kind: A1
- Application number: 16/434,512
- Filed: 2019-06-07
- Published: 2019-10-17
- Earliest claimed: 2016-12-08
- Assignees: Intellia Therapeutics, Inc.
- Applicants: Intellia Therapeutics, Inc.
- Inventors: Amy Madison Rhoden Smith; David V. Morrissey; Walter Strapps
- Web page: https://patentgrep.com/patent/US20190316121A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.

## Claims

### Claim 1

A single guide RNA (sgRNA) comprising a 5′ end modification and one or more modification in one or more of:
a. the upper stem region;
b. the hairpin 1 region; and
c. the hairpin 2 region,
wherein the 5′ end modification comprises at least two phosphorothioate (PS) linkages within the first seven nucleotides at the 5′ end of the 5′ terminus.

### Claim 2 (depends on 1)

The sgRNA of claim 1, wherein at least one modification comprises a 2′-O-methyl (2′-O-Me) modified nucleotide.

### Claim 3 (depends on 1, 2)

The sgRNA of claim 1 or claim 2, wherein at least one modification comprises a 2′-fluoro (2′-F) modified nucleotide.

### Claim 4 (depends on 1, 2, 3)

The sgRNA of any one of claims 1-3, wherein at least one modification comprises a phosphorothioate (PS) bond between nucleotides.

### Claim 5 (depends on 1, 2, 3, 4)

The sgRNA of any one of claims 1-4, wherein the sgRNA comprises one or more modifications in the upper stem region.

### Claim 6 (depends on 5)

The sgRNA of claim 5, comprising modifications at US1 to US12.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The sgRNA of any one of claims 1-6, wherein the sgRNA comprises one or more modifications in the hairpin 1 region.

### Claim 8 (depends on 7)

The sgRNA of claim 7, wherein the sgRNA comprises a modification at H1-1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The sgRNA of any one of claims 1-8, wherein the sgRNA comprises one or more modifications in the hairpin 2 region.

### Claim 10 (depends on 9)

The sgRNA of claim 9, wherein the sgRNA comprises a modification at H2-1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The sgRNA of any one of claims 1-10, wherein the sgRNA comprises modifications at H1-1 to H1-12.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The sgRNA of any one of claims 1-11, wherein the sgRNA comprises modifications at H2-1 to H2-15.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The sgRNA of any one of claims 1-12, wherein the sgRNA comprises one or more modifications in each of the upper stem region, the hairpin 1 region, and the hairpin 2 region.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The sgRNA of any one of claims 1-13, wherein the sgRNA comprises a modified nucleotide between hairpin 1 and hairpin 2 regions.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The sgRNA of any one of claims 1-14, further comprising a lower stem region comprising a modification.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The sgRNA of any one of claims 1-15, further comprising a 3′ terminus region comprising a modification.

### Claim 17 (depends on 16)

The sgRNA of claim 16, further comprising a 3′ end modification in the 3′ terminus.

### Claim 18 (depends on 17)

The sgRNA of claim 17, wherein at least two of the last four nucleotides at the 3′ end of the 3′ terminus are modified.

### Claim 19 (depends on 17)

The sgRNA of claim 17, wherein at least two of the last four nucleotides at the 3′ end of the 3′ terminus are modified with 2′-O-Me, 2′-F, or 2′-O-moe.

### Claim 20 (depends on 17, 18, 19)

The sgRNA of any one of claims 17-19, further comprising phosphorothioate (PS) bonds between one or more of the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The sgRNA of any one of claims 1-20, further comprising a bulge region comprising a modification.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The sgRNA of any one of claims 1-21, further comprising a nexus region comprising a modification.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The sgRNA of any one of claims 1-22, wherein at least the first three nucleotides at the 5′ end of the 5′ terminus, and the last three nucleotides at the 3′ end of the 3′ terminus are modified.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The sgRNA of any one of claims 1-23, wherein the first four nucleotides at the 5′ end of the 5′ terminus, and the last four nucleotides at the 3′ end of the 3′ terminus are linked with phosphorothioate (PS) bonds.

### Claim 25 (depends on 24)

The sgRNA of claim 24, wherein the end modifications comprise 2′-O-Me.

### Claim 26 (depends on 24)

The sgRNA of claim 24, wherein the end modifications comprise 2′-F.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The sgRNA of any one of claims 1-26, wherein the first four nucleotides at the 5′ end of the 5′ terminus and the last four nucleotides at the 3′ end of the 3′terminus are linked with a PS bond, and wherein the first three nucleotides at the 5′ end of the 5′ terminus and the last three nucleotides at the 3′ end of the 3′ terminus comprise 2′-O-Me modifications.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The sgRNA of any one of claims 1-26, wherein the first four nucleotides at the 5′ terminus and the last four nucleotides at the 3′ terminus are linked with a PS bond, and wherein the first three nucleotides at the 5′ terminus and the last three nucleotides at the 3′ terminus comprise 2′-O-Me, 2′-F, and/or 2′-O-moe modifications.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The sgRNA of any one of claims 1-28, wherein LS1, LS6, LS7, LS8, LS11, and/or LS12 are modified with 2′-O-Me.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The sgRNA of any one of claims 1-29, wherein each of the nucleotides in the bulge region are modified with 2′-O-Me.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The sgRNA of any one of claims 1-29, wherein at least 50% of the nucleotides in the bulge region are modified with 2′-O-Me.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The sgRNA of any one of claims 1-31, wherein each of the nucleotides in the upper stem region are modified with 2′-O-Me.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The sgRNA of any one of claims 1-32, wherein N16, N17, and/or N18 in the nexus region are modified with 2′-O-Me.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The sgRNA of any one of claims 1-32, wherein N15, N16, N17, and/or N18 in the nexus region are modified.

### Claim 35 (depends on 33, 34)

The sgRNA of claim 33 or claim 34, wherein the modifications in the nexus region are selected from 2′-O-Me and 2′F.

### Claim 36 (depends on 32, 33, 34, 35)

The sgRNA of any one of claims 32-35, wherein N16, N17, and N18 are linked with PS bonds.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The sgRNA of any one of claims 1-36, wherein each of the nucleotides in the hairpin 1 region are modified with 2′-O-Me.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The sgRNA of any one of claims 1-37, wherein each of the nucleotides in the hairpin 2 region are modified with 2′-O-Me.

### Claim 39

A single guide RNA (sgRNA) comprising 2′-O-Me modified nucleotides at the following positions:
a. the first three nucleotides at the 5′ end of the 5′ terminus;
b. LS1, LS6, LS7, LS8, LS11, and/or LS12 in the lower stem region;
c. B1 and/or B2 in the bulge region;
d. each nucleotide in the upper stem region;
e. N16, N17, and/or N18 in the nexus region;
f. each nucleotide in the hairpin 1 region;
g. each nucleotide in the hairpin 2 region; and
h. the last four nucleotides at the 3′ terminus.

### Claim 40 (depends on 39)

The sgRNA of claim 39, wherein B3-B6 are modified with 2′-O-Me.

### Claim 41 (depends on 39)

The sgRNA of claim 39, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 42

The sgRNA of any one of the preceding claims, wherein LS9 and LS10 are modified, e.g. with 2′-F or 2′-OMe.

### Claim 43

The sgRNA of any one of the preceding claims, wherein N15, N16, N17, and N18 are modified, e.g. with 2′-F or 2′-OMe.

### Claim 44

The sgRNA of any one of the preceding claims, wherein H2-9, H2-10, H2-11, H2-12, H2-13, H2-14, and H2-15 are modified with 2′-F.

### Claim 45

The sgRNA of any one of the preceding claims, wherein the second to last, third to last, and fourth to last nucleotides at the 3′ terminus are modified with 2′-F.

### Claim 46

A single guide RNA (sgRNA) comprising 2′-F modified nucleotides at the following positions:
a. LS9 and LS10 in the lower stem region;
b. N15, N16, N17, and N18 in the nexus region; and
c. H2-9, H2-10, H2-11, H2-12, H2-13, H2-14, and H2-15 in the hairpin 2 region.

### Claim 47 (depends on 46)

The sgRNA of claim 46, further comprising 2′-F modified nucleotides at the second to last, third to last, and fourth to last nucleotides at the 3′ terminus.

### Claim 48 (depends on 46, 47)

The sgRNA of claim 46 or claim 47, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 49 (depends on 46, 47, 48)

The sgRNA of any one of claims 46-48, further comprising 2′-O-Me or 2′-F modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus, and 2′-O-Me or 2′-F modified nucleotides at the three of the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 50

A single guide RNA (sgRNA) comprising:
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at US1-US12;
c. 2′-O-Me modified nucleotides at H1-1-H1-12;
d. 2′-O-Me modified nucleotides at H2-1-H2-15; and
e. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 51 (depends on 50)

The sgRNA of claim 50 further comprising 2′-O-Me modified nucleotides at LS1 and/or LS6.

### Claim 52 (depends on 50, 51)

The sgRNA of claim 50 or claim 51 further comprising a 2′-O-Me modified nucleotide between Hairpin 1 and Hairpin 2.

### Claim 53

A single guide RNA (sgRNA) comprising:
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-F modified nucleotides at LS1-LS6;
c. 2′-O-Me modified nucleotides at US1-US12;
d. 2′-O-Me modified nucleotides at H1-1-H1-12;
e. a 2′-O-Me modified nucleotide between hairpin 1 and hairpin 2;
f. 2′-O-Me modified nucleotides at H2-1-H2-15; and
g. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 54

A single guide RNA (sgRNA) comprising:
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-F modified nucleotides at LS2-LS5;
c. 2′-O-Me modified nucleotides at LS1 and LS6;
d. 2′-O-Me modified nucleotides at US1-US12;
e. 2′-O-Me modified nucleotides at H1-1-H1-12;
f. a 2′-O-Me modified nucleotide between hairpin 1 and hairpin 2;
g. 2′-O-Me modified nucleotides at H2-1-H2-15; and
h. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 55

A single guide RNA (sgRNA) comprising
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at US1-US12;
c. 2′-O-Me modified nucleotides at LS7, LS8, LS11, and LS12;
d. 2′-O-Me modified nucleotides at H1-1-H1-12;
e. a 2′-O-Me modified nucleotide between hairpin 1 and hairpin 2;
f. 2′-O-Me modified nucleotides at H2-1-H2-15; and
g. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 56

A single guide RNA (sgRNA) comprising
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at US1-US12;
c. 2′-O-Me modified nucleotides at LS7, LS8, LS11, and LS12;
d. 2′-F modified nucleotides at LS9 and LS10;
e. 2′-O-Me modified nucleotides at H1-1-H1-12;
f. a 2′-O-Me modified nucleotide between hairpin 1 and hairpin 2;
g. 2′-O-Me modified nucleotides at H2-1-H2-15; and
h. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 57

A single guide RNA (sgRNA) comprising
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at US1-US12;
c. 2′-O-Me modified nucleotides at LS8, LS10, and LS12;
d. 2′-O-F modified nucleotides at LS7, LS9, and LS11;
e. 2′-O-Me modified nucleotides at H1-1-H1-12;
f. a 2′-O-Me modified nucleotide between hairpin 1 and hairpin 2;
g. 2′-O-Me modified nucleotides at H2-1-H2-15; and
h. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 58

A single guide RNA (sgRNA) comprising:
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at LS1, LS6, LS7, LS8, LS11, and LS12
c. 2′-O-Me modified nucleotides at US1-US12;
d. 2′-O-Me modified nucleotides at H1-1-H1-12;
e. a 2′-O-Me modified nucleotide between hairpin 1 and hairpin 2;
f. 2′-O-Me modified nucleotides at H2-1-H2-15; and
g. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 59

A single guide RNA (sgRNA) comprising
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at LS1, LS6, LS7, LS8, LS11, and LS12;
c. 2′-F modified nucleotides at LS9 and LS10;
d. 2′-O-Me modified nucleotides at US1-US12;
e. 2′-O-Me modified nucleotides at H1-1-H1-12;
f. a 2′-O-Me modified nucleotide between hairpin 1 and hairpin 2;
g. 2′-O-Me modified nucleotides at H2-1-H2-15; and
h. 2′-O-Me modified nucleotides at the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 60

A single guide RNA (sgRNA) comprising
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at US1-US12;
c. 2′-O-Me modified nucleotides at H1-1-H1-12;
d. a 2′-O-Me modified nucleotide between Hairpin 1 and Hairpin 2;
e. 2′-O-Me modified nucleotides at H2-1-H2-8;
f. 2′-F modified nucleotides at H2-9-H2-15;
g. 2′-F modified nucleotides at the second from last, third from last, and fourth from last nucleotide at the 3′ terminus; and
h. a 2′-O-Me modified nucleotide at the last nucleotide at the 3′ end of the 3′ terminus.

### Claim 61

A single guide RNA (sgRNA) comprising
a. 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus;
b. 2′-O-Me modified nucleotides at US1-US12;
c. 2′-O-Me modified nucleotides at H1-2, H1-4, H1-6, H1-8, H1-10, and H1-12;
d. 2′-F modified nucleotides at H1-1, H1-3, H1-5, H1-7, H1-9, and H1-11;
e. a 2′-F modified nucleotide between hairpin 1 and hairpin 2;
f. 2′-F modified nucleotides at H2-2, H2-4, H2-6, H2-8, H2-10, H2-12; and H2-14;
g. 2′-O-Me modified nucleotides at H2-1, H2-3, H2-5, H2-7, H2-9, H2-11; H2-13, and H2-15;
h. 2′-F modified nucleotides at the second from last, and fourth from last nucleotide at the 3′ terminus; and
i. 2′-O-Me modified nucleotide at the third from last, and last nucleotide at the 3′ end of the 3′ terminus.

### Claim 62 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The sgRNA of any of claims 50-61 further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 63 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The sgRNA of any of claims 50-61 further comprising at least one phosphorothioate (PS) bond within the first seven nucleotides at the 5′ end of the 5′ terminus.

### Claim 64

A single guide RNA (sgRNA) comprising
a. 2′-O-Me modified nucleotides LS8, LS10, LS12, H1-2, H1-4, H1-6, H1-8, H1-10, H1-12, H2-1, H2-3, H2-5, H2-7, H2-9, H2-11, H2-13, and H2-15; and
b. 2′-F modified nucleotides at LS7, LS9, LS11; H1-1, H1-3, H1-5, H1-7, H1-9, H1-11, H1-13, H2-2, H2-4, H2-6, H2-8, H2-10, H2-12, and H2-14.

### Claim 65 (depends on 64)

The sgRNA of claim 64, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 66 (depends on 64, 65)

The sgRNA of claim 64 or claim 65, further comprising
a. 2′-O-Me modified nucleotides at the last and third to last nucleotide at the 3′ end of the 3′ terminus; and
b. 2′-F modified nucleotides at the second to last and fourth to last nucleotide at the 3′ end of the 3′ terminus.

### Claim 67

An sgRNA comprising any of SEQ ID Nos: 228-332, including the modifications of Table 4.

### Claim 68

An sgRNA comprising any of SEQ ID Nos: 235-240, 265-285, and 309-329, including the modifications of Table 4.

### Claim 69

An sgRNA comprising SEQ ID No: 240.

### Claim 70

An sgRNA comprising SEQ ID No. 240, including the modifications of Table 4.

### Claim 71

An sgRNA comprising SEQ ID No: 242, including the modifications of Table 4.

### Claim 72

An sgRNA comprising the modifications of SEQ ID No: 242, as depicted in Table 4.

### Claim 73

An sgRNA comprising SEQ ID No: 358.

### Claim 74

An sgRNA comprising nucleic acids having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleic acids of any one of SEQ ID Nos: 235-240, 265-285, and 309-329, wherein the modification at each nucleotide of the sgRNA that corresponds to a nucleotide of the reference sequence identifier in Table 4, is identical to or equivalent to the modification shown in the reference sequence identifier in Table 4.

### Claim 75 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74)

The sgRNA of any one of claims 66-74, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ terminus.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The sgRNA of any one of claims 1-74, further comprising at least three PS bonds linking the nucleotides in the hairpin 1 region.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The sgRNA of any one of claims 1-75, further comprising at least three PS bonds linking the nucleotides in the hairpin 2 region.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The sgRNA of any one of claims 1-76, further comprising at least three PS bonds linking the nucleotides in the upper stem region.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The sgRNA of any one of claims 1-77, wherein the sgRNA forms a ribonucleoprotein complex with an S. pyogenes Cas9.

### Claim 79

A guide RNA comprising 2′-O-Me modifications at each nucleotide in the upper stem region.

### Claim 80

A guide RNA comprising 2′-O-Me modifications at one, two, three, or four, five, six, seven, eight, nine, ten, or eleven of the following nucleotides: US1, US2, US3, US4, US5, US6, US7, US8, US9, US10, US11, and US12.

### Claim 81

A guide RNA comprising 2′-O-Me modifications at 50% or more of the nucleotides in the hairpin 1 and hairpin 2 regions.

### Claim 82

A guide RNA comprising 2′-O-Me modifications at each nucleotide in the upper stem region and 2′-O-Me modifications at 50% or more of the nucleotides in the hairpin 1 and hairpin 2 regions.

### Claim 83

A guide RNA comprising or consisting of 2′-O-Me modifications at each nucleotide starting at H2-1 or H2-2 through the last nucleotide of the 3′ terminus.

### Claim 84

A guide RNA comprising or consisting of a 2′-O-Me modification at LS1 and/or LS6 and no modification at LS2-LS5.

### Claim 85

A guide RNA comprising 2′-O-Me modified nucleotides at 2 or more of LS8, LS9, LS10, LS11, and/or LS12.

### Claim 86 (depends on 85)

The guide RNA of claim 85, wherein at least LS8 and LS10 are modified with 2′-O-Me.

### Claim 87 (depends on 79, 80, 81, 82, 83, 84, 85, 86)

The guide RNA of any of claims 79-86, further comprising 2′-O-Me modifications at 50% or more of the nucleotides in the nexus region.

### Claim 88 (depends on 87)

The guide RNA of claim 87, wherein at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the nucleotides in the nexus region are modified with 2′-O-Me.

### Claim 89

A guide RNA comprising 2′-O-Me modifications at up to 50% of the nucleotides in the nexus region.

### Claim 90

A guide RNA comprising 2′-O-Me modifications at four or more nucleotides in the nexus region.

### Claim 91 (depends on 90)

The guide RNA of claim 90, wherein at least one, two, three, four, or five of nucleotides N2-N6 in the nexus region are modified with 2′-O-Me.

### Claim 92

A guide RNA comprising 2′-O-Me modified nucleotides at ten or more nucleotides in the nexus region.

### Claim 93 (depends on 92)

The guide RNA of claim 92, wherein at least N2-N6 are modified with 2′-O-Me.

### Claim 94

A guide RNA comprising 2′-O-Me modifications at 50% or more of the nucleotides in the bulge region.

### Claim 95 (depends on 94)

The guide RNA of claim 94, wherein at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the nucleotides in the bulge region are modified with 2′-O-Me.

### Claim 96 (depends on 94)

The guide RNA of claim 94, wherein B2, B3, and/or B4 are modified with 2′-O-Me.

### Claim 97

A guide RNA comprising 2′-O-Me modified nucleotides at three or more nucleotides in the bulge region.

### Claim 98 (depends on 97)

The guide RNA of claim 97, wherein B2, B3, and/or B4 are modified with 2′-O-Me.

### Claim 99

A guide RNA comprising the nucleotides of SEQ ID NO: 357 with the modification pattern of the guide RNA of any preceding claim.

### Claim 100

The guide RNA comprising the nucleotides of SEQ ID NO: 356 with the modification pattern of the guide RNA of any preceding claim.

### Claim 101 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, further comprising 2′-O-Me modifications at the first three, four, or five nucleotides at the 5′ end of the 5′ terminus region.

### Claim 102 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, further comprising 2′-O-Me modifications at the last three, last four, or last five nucleotides at the 3′ end of the 3′ terminus region.

### Claim 103 (depends on 102)

The guide RNA of claim 102, wherein the last nucleotide at the 3′ end of the 3′ terminus region is not modified.

### Claim 104 (depends on 102)

The guide RNA of claim 102, wherein only the second to last and third to last nucleotide at the 3′ end of the 3′ terminus region are modified.

### Claim 105 (depends on 102)

The guide RNA of claim 102, wherein only the second to last, third to last, and fourth to last nucleotide in the 3′ terminus region are modified.

### Claim 106 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, further comprising PS bonds between the first three, four, or five nucleotides at the 5′ end of the 5′ terminus.

### Claim 107 (depends on 106)

The guide RNA of claim 106, wherein the first four nucleotides at the 5′ end of the 5′ terminus are linked with PS bonds.

### Claim 108 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, further comprising PS bonds between the last three, four, or five nucleotides at the 3′ end of the 3′ terminus.

### Claim 109 (depends on 108)

The guide RNA of claim 108, wherein the last four nucleotides at the 3′ end of the 3′ terminus are linked with PS bonds.

### Claim 110 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein the first three or four nucleotides at the 5′ end of the 5′ terminus, and the last three or four nucleotides at the 3′ end of the 3′ terminus comprise 2′-O-Me modifications.

### Claim 111 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein the first three or four nucleotides at the 5′ end of the 5′ terminus are linked with PS bonds, and the last three or four nucleotides at the 3′ end of the 3′ terminus are linked with PS bonds.

### Claim 112 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein the first three or four nucleotides at the 5′ end of the 5′ terminus comprise 2′-O-Me modifications and are linked with PS bonds, and the last three or four nucleotides at the 3′ end of the 3′ terminus comprise 2′-O-Me modifications and are linked with PS bonds.

### Claim 113 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein at least two of nucleotides LS8, LS9, LS10, LS11, and LS12 comprise 2′-O-Me modifications.

### Claim 114 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein at least LS8 and LS10 are modified with 2′-O-Me.

### Claim 115 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein at least 50% of the nucleotides in the nexus region are modified with 2′-O-Me.

### Claim 116 (depends on 115)

The guide RNA of claim 115, wherein at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the nucleotides in the nexus region are modified with 2′-O-Me.

### Claim 117 (depends on 115)

The guide RNA of claim 115, wherein at least N2-N6 are modified with 2′-O-Me.

### Claim 118 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein at least ten of the nucleotides in the nexus region are modified with 2′-O-Me.

### Claim 119 (depends on 115)

The guide RNA of claim 115, wherein at least N2-N6 are modified with 2′-O-Me.

### Claim 120 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein at least 50% of the nucleotides in the bulge region are modified with 2′-O-Me.

### Claim 121 (depends on 120)

The guide RNA of claim 120, wherein at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the nucleotides in the bulge region are modified with 2′-O-Me.

### Claim 122 (depends on 121)

The guide RNA of claim 121, wherein B2, B3, and/or B4 are modified with 2′-O-Me.

### Claim 123 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The guide RNA of any one of claims 79-100, wherein at least three of the nucleotides in the bulge region are modified with 2′-O-Me.

### Claim 124 (depends on 123)

The guide RNA of claim 123, wherein B2, B3, and/or B4 are modified with 2′-O-Me.

### Claim 125 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The guide RNA of any one of claims 79-124, wherein the guide RNA is an sgRNA.

### Claim 126 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The guide RNA of any one of claims 79-125, wherein the guide RNA is a dgRNA.

### Claim 127 (depends on 81, 82)

The guide RNA of claim 81 or 82, wherein at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the nucleotides in the hairpin 1 and hairpin 2 regions are modified with 2′-OMe.

### Claim 128 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127)

The guide RNA of any one of claims 79-127, wherein the gRNA forms a ribonucleoprotein complex with an S. pyogenes Cas9.

### Claim 129

A single guide RNA (sgRNA) comprising or consisting of 2′-O-Me modified nucleotides at:
a. the first three nucleotides at the 5′ end of the 5′ terminus;
b. each nucleotide in the upper stem region;
c. each nucleotide in the hairpin 1 region;
d. the nucleotide between hairpin 1 and hairpin 2;
e. each nucleotide in the hairpin 2 region; and
f. the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 130 (depends on 129)

The sgRNA of claim 129, further comprising PS bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 131

An sgRNA having the modification pattern shown in SEQ ID NO: 350, 351, 352, or 353, as depicted in Table 4.

### Claim 132

A single guide RNA (sgRNA) comprising or consisting of 2′-O-Me modified nucleotides at:
a. the first three, four, five, or seven nucleotides at the 5′ end of the 5′ terminus;
b. each nucleotide in the upper stem region;
c. each nucleotide in the hairpin 1 region;
d. the nucleotide between hairpin 1 and hairpin 2;
e. each nucleotide in the hairpin 2 region; and
f. the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 133

A single guide RNA (sgRNA) comprising or consisting of 2′-O-Me modified nucleotides at:
a. the first three, four, five, or seven nucleotides at the 5′ end of the 5′ terminus;
b. each of nucleotides US1, US2, US3, US4, US5, US6, US7, USB, US9, US10, US11 and US12;
c. each of nucleotides H1-1, H1-2, H1-3, H1-4, H1-5, H1-6, H1-7, H1-8, H1-9, H1-10, H1-11, and H1-12;
d. the nucleotide between hairpin 1 and hairpin 2;
e. each of nucleotides H2-1, H2-2, H2-3, H2-4, H2-5, H2-6, H2-7, H2-8, H2-9, H2-10, H2-11, H2-12, H2-13, H2-14, and H2-15; and
f. the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 134 (depends on 129, 130, 131, 132, 133)

The sgRNA of any one of claims 129-133, further comprising PS bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 135

An sgRNA having the modification pattern of SEQ ID NO: 350, 351, 352, or 353 as shown in Table 4.

### Claim 136 (depends on 129, 130, 131, 132, 133, 134, 135)

The sgRNA of any one of claims 129-135, wherein the sgRNA forms a ribonucleoprotein complex with an S. pyogenes Cas9.

### Claim 137

A crispr RNA (crRNA) comprising one or more modifications within one or more of the following regions:
a. the first five nucleotides at the 5′ end of the 5′ terminus;
b. the lower stem region;
c. the bulge region;
d. the upper stem region; and
e. the last five nucleotides at the 3′ end of the crRNA.

### Claim 138 (depends on 136)

The crRNA of claim 136, further comprising a 5′ end modification, wherein the 5′ end modification comprises one or more phosphorothioate linkages within the first seven nucleotides at the 5′ end of the 5′ terminus.

### Claim 139 (depends on 136)

The crRNA of claim 136, further comprising a 5′ end modification, wherein the 5′ end modification comprises at least two phosphorothioate linkages within the first seven nucleotides at the 5′ end of the 5′ terminus.

### Claim 140 (depends on 137, 138, 139)

The crRNA of any one of claims 137-139, wherein at least one modification comprises a 2′-O-methyl (2′-O-Me) modified nucleotide.

### Claim 141 (depends on 137, 138, 139, 140)

The crRNA of any one of claims 137-140, wherein at least one modification comprises a 2′-fluoro (2′-F) modified nucleotide.

### Claim 142 (depends on 137, 138, 139, 140, 141)

The crRNA of any one of claims 137-141, wherein at least one modification comprises a phosphorothioate (PS) bond between nucleotides.

### Claim 143 (depends on 137, 138, 139, 140, 141, 142)

The crRNA of any one of claims 137-142, wherein the first three nucleotides at the 5′ end of the 5′ terminus and the last three nucleotides at the 3′ end of the 3′ terminus are modified.

### Claim 144 (depends on 137, 138, 139, 140, 141, 142, 143)

The crRNA of any one of claims 137-143, wherein the first four nucleotides at the 5′ end of the 5′ terminus, and the last four nucleotides at the 3′ end of the 3′ terminus are linked with phosphorothioate (PS) bonds.

### Claim 145 (depends on 143)

The crRNA of claim 143, wherein the modification comprises 2′-O-Me.

### Claim 146 (depends on 143)

The crRNA of claim 143, wherein the modification comprises 2′-F.

### Claim 147 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146)

The crRNA of any one of claims 137-146, wherein the first four nucleotides at the 5′ end of the 5′ terminus and the last four nucleotides at the 3′ end of the 3′ terminus are linked with a PS bond, and wherein the first three nucleotides at the 5′ end of the 5′ terminus and the last three nucleotides at the 3′ end of the 3′ terminus comprise 2′-O-Me modifications.

### Claim 148 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146)

The crRNA of any one of claims 137-146, wherein the first four nucleotides at the 5′ end of the 5′ terminus and the last four nucleotides at the 3′ end of the 3′ terminus are linked with a PS bond, and wherein the first three nucleotides at the 5′ end of the 5′ terminus and the last three nucleotides at the 3′ end of the 3′ terminus comprise 2′-F modifications.

### Claim 149 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148)

The crRNA of any one of claims 137-148, wherein LS1 and LS6 are modified with 2′-O-Me.

### Claim 150 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149)

The crRNA of any one of claims 137-149, wherein each of the nucleotides in the upper stem region are modified with 2′-O-Me.

### Claim 151

A crispr RNA (crRNA) comprising 2′-O-Me modified nucleotides at:
a. LS1 and LS6 in the lower stem region; and
b. each nucleotide in the upper stem region.

### Claim 152 (depends on 151)

The crRNA of claim 151, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 153 (depends on 151, 152)

The crRNA of claim 151 or claim 152, further comprising 2′-O-Me or 2′-F modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus, and 2′-O-Me or 2′-F modified nucleotides at the last three nucleotides at the 3′ end of the 3′ terminus.

### Claim 154 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153)

The crRNA of any of claims 137-153, wherein LS1, LS2, and LS6 are modified with 2′-F.

### Claim 155 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154)

The crRNA of any of claims 137-154, wherein each nucleotide in the bulge region is modified with 2′-F.

### Claim 156

A crispr RNA (crRNA) comprising 2′-F modified nucleotides at:
a. LS1, LS2, and LS6 in the lower stem region; and
b. each nucleotide in the bulge region.

### Claim 157 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156)

The crRNA of any one of claims 137-156, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 158 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157)

The crRNA of any one of claims 137-157, further comprising 2′-O-Me or 2′-F modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus, and 2′-O-Me or 2′-F modified nucleotides at the last three nucleotides at the 3′ end of the 3′ terminus.

### Claim 159

A crRNA comprising any one of SEQ ID Nos: 1-187, including the modifications of Table 4.

### Claim 160

A crRNA comprising any one of SEQ ID Nos: 19-31, 53-73, 104-130, and 161-187, including the modifications of Table 4.

### Claim 161

A crRNA comprising nucleic acids having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to any one of SEQ ID Nos: 19-31, 53-73, 104-130, and 161-187, wherein the modification at each nucleotide of the crRNA that corresponds to a nucleotide of the reference sequence identifier in Table 4, is identical to or equivalent to the modification shown in the reference sequence identifier in Table 4.

### Claim 162 (depends on 159, 160, 161)

The crRNA of any one of claims 159-161, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 163 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162)

The crRNA of any one of claims 137-162, wherein the crRNA combined with a trRNA forms a ribonucleoprotein complex with an S. pyogenes Cas9.

### Claim 164

A tracr RNA (trRNA) comprising one or more modifications within one or more of the following regions:
a. the first five nucleotides at the 5′ end of the 5′ terminus;
b. the upper stem region;
c. the bulge region;
d. the lower stem region;
e. the nexus region;
f. the hairpin 1 region;
g. the hairpin 2 region; and
h. the last five nucleotides at the 3′ end of the 3′ terminus.

### Claim 165 (depends on 164)

The trRNA of claim 164, wherein at least one modification comprises a 2′-O-methyl (2′-O-Me) modified nucleotide.

### Claim 166 (depends on 164, 165)

The trRNA of claim 164 or claim 165, wherein at least one modification comprises a 2′-fluoro (2′-F) modified nucleotide.

### Claim 167 (depends on 164, 165, 166)

The trRNA of any one of claims 164-166, wherein at least one modification comprises a phosphorothioate (PS) bond between nucleotides.

### Claim 168 (depends on 164, 165, 166, 167)

The trRNA of any one of claims 164-167, wherein the first four nucleotides at the 5′ end of the 5′ terminus, and the last four nucleotides at the 3′ end of the 3′ terminus are linked with phosphorothioate (PS) bonds.

### Claim 169 (depends on 164, 165, 166, 167, 168)

The trRNA of any one of claims 164-168, wherein the first three nucleotides at the 5′ end of the 5′ terminus and the last three nucleotides at the 3′ end of the 3′ terminus are modified.

### Claim 170 (depends on 169)

The trRNA of claim 169, wherein the modification comprises 2′-O-Me.

### Claim 171 (depends on 169)

The trRNA of claim 169, wherein the modification comprises 2′-F.

### Claim 172 (depends on 164, 165, 166, 167, 168, 169, 170, 171)

The trRNA of any one of claims 164-171, wherein the first four nucleotides at the 5′ end of the 5′ terminus and the last four nucleotides at the 3′ end of the 3′ terminus are linked with a PS bond, and wherein the first three nucleotides at the 5′ end of the 5′ terminus and the last three nucleotides at the 3′ end of the 3′ terminus comprise 2′-O-Me modifications.

### Claim 173 (depends on 164, 165, 166, 167, 168, 169, 170, 171)

The trRNA of any one of claims 164-171, wherein the first four nucleotides at the 5′ end of the 5′ terminus and the last four nucleotides at the 3′ end of the 3′terminus are linked with a PS bond, and wherein the first three nucleotides at the 5′ end of the 5′ terminus and the last three nucleotides at the 3′ end of the 3′ terminus comprise 2′-F modifications.

### Claim 174 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The trRNA of any one of claims 164-173, wherein each nucleotide in the upper stem region is modified with 2′-O-Me.

### Claim 175 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174)

The trRNA of any one of claims 164-174, wherein B1 and B2 within the bulge region are modified with 2′-O-Me.

### Claim 176 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175)

The trRNA of any one of claims 164-175, wherein N3, N4, N5, N15, N16, N17, and/or N18 in the nexus region are modified with 2′-O-Me.

### Claim 177 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The trRNA of any one of claims 164-176, wherein each nucleotide in the hairpin 1 region is modified with 2′-O-Me.

### Claim 178 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177)

The trRNA of any one of claims 164-177, wherein each nucleotide in the hairpin 2 region is modified with 2′-O-Me.

### Claim 179

A tracr RNA (trRNA) comprising 2′-O-Me modified nucleotides at:
a. each nucleotide in the upper stem;
b. B1 and/or B2 within the bulge region;
c. N3, N4, N5, N15, N16, N17, and/or N18 in the nexus region;
d. each nucleotide in the hairpin 1 region; and
e. each nucleotide in the hairpin 2 region.

### Claim 180 (depends on 179)

The trRNA of claim 179, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 181 (depends on 179, 180)

The trRNA of claim 179 or claim 180, further comprising 2′-O-Me or 2′-F modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus, and 2′-O-Me or 2′-F modified nucleic acids at the last three nucleotides at the 3′ end of the 3′ terminus.

### Claim 182 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The trRNA of any of claims 164-181, wherein N15, N16, N17, and N18 are modified with 2′-F.

### Claim 183 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The trRNA of any of claims 164-182, wherein LS1, LS3, and LS5 are modified with 2′-F, and LS2, LS4, and LS6 are modified with 2′-O-Me.

### Claim 184 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183)

The trRNA of any one of claims 164-183, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 185 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184)

The trRNA of any one of claims 164-184, further comprising 2′-O-Me or 2′-F modified nucleotides at the first three nucleotides at the 5′ end of the 5′ terminus, and 2′-O-Me or 2′-F modified nucleotides at the last three nucleotides at the 3′ end of the 3′ terminus.

### Claim 186

A trRNA comprising any one of SEQ ID Nos: 188-227, including the modifications of Table 4.

### Claim 187

A trRNA comprising nucleic acids having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to any one of SEQ ID Nos: 188-227, wherein the modification at each nucleotide of the trRNA that corresponds to a nucleotide of the reference sequence identifier in Table 4, is identical to or equivalent to the modification shown in the reference sequence identifier in Table 4.

### Claim 188

The trRNA of any one of claims—186-187, further comprising three phosphorothioate (PS) bonds linking the first four nucleotides at the 5′ end of the 5′ terminus and three PS bonds linking the last four nucleotides at the 3′ end of the 3′ terminus.

### Claim 189 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188)

The trRNA of any one of claims 164-188, wherein the trRNA combined with a crRNA forms a ribonucleoprotein complex with an S. pyogenes Cas9.

### Claim 190

A dual guide comprising a crRNA and a trRNA, wherein the crRNA comprises any one of SEQ ID Nos: 1-187 as depicted in Table 4, and wherein the trRNA comprises the nucleic acids of any one of SEQ ID Nos: 188-227 as depicted in Table 4.

### Claim 191 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

A dual guide comprising a crRNA of any one of claims 137-163 and a trRNA of any one of claims 164-189.

### Claim 192 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163)

A dual guide comprising a crRNA of any one of claims 137-163 and an unmodified trRNA.

### Claim 193 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

A dual guide comprising an unmodified crRNA and a trRNA of any one of claims 137-189.

### Claim 194 (depends on 190, 191, 192, 193)

A dual guide of any one of claims 190-193, wherein the dual guide forms a ribonucleoprotein complex with an S. pyogenes Cas9.

### Claim 195 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 129, 130, 131, 132, 133, 134, 135, 136)

An LNP composition comprising an sgRNA of any one of claims 1-78 and 129-136.

### Claim 196 (depends on 1, 193)

An LNP composition comprising a gRNA comprising or consisting of the RNA of any one of claims 1-193.

### Claim 197 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 129, 130, 131, 132, 133, 134, 135, 136)

A composition comprising an sgRNA of any one of claims 1-78 and 129-136 associated with a lipid nanoparticle (LNP).

### Claim 198 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163)

A composition comprising a crRNA of any of claims 137-163 associated with a lipid nanoparticle (LNP).

### Claim 199 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

A composition comprising a trRNA of any of claims 164-189 associated with a lipid nanoparticle (LNP).

### Claim 200 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199)

A composition comprising the sgRNA of any one of claims 1-78 and 129-136, the gRNA of any one of claims 79-128, the crRNA of any one of claims 137-163, the trRNA of any one of claims 164-189, the dgRNA of any one of claims 190-194, or the composition of any one of claims 195-199, further comprising a nuclease or an mRNA which encodes the nuclease.

### Claim 201 (depends on 200)

The composition of claim 200, wherein the nuclease is a Cas protein.

### Claim 202 (depends on 201)

The composition of claim 201, wherein the Cas protein is a Cas9.

### Claim 203 (depends on 202)

The composition of claim 202, wherein the Cas9 is an S. pyogenes Cas9.

### Claim 204 (depends on 200, 201, 202, 203)

The composition of any one of claims 200-203, wherein the nuclease is a nickase.

### Claim 205 (depends on 200, 201, 202, 203, 204)

The composition of any one of claims 200-204, wherein the nuclease is modified.

### Claim 206 (depends on 205)

The composition of claim 205, wherein the modified nuclease comprises a nuclear localization signal (NLS).

### Claim 207 (depends on 200, 201, 202, 203, 204, 205, 206)

The composition of any one of claims 200-206, comprising an mRNA which encodes the nuclease.

### Claim 208 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207)

A pharmaceutical formulation comprising the sgRNA of any one of claims 1-78 and 129-136, the gRNA of any one of claims 79-128, the crRNA of any one of claims 137-163, the trRNA of any one of claims 164-189, the dgRNA of any one of claims 190-194, or the composition of any one of claims 195-207 and a pharmaceutically acceptable carrier.

### Claim 209 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208)

A method of modifying a target DNA comprising, delivering a Cas protein or a nucleic acid encoding a Cas protein, and any one or more of the following to a cell:
a. the sgRNA of any one of claims 1-78 and 129-136;
b. the gRNA of any one of claims 79-128;
c. the crRNA of any one of claims 137-163;
d. the trRNA of any one of claims 164-189;
e. the dgRNA of any one of claims 190-194;
f. the composition of any one of claims 195-207; or
g. the pharmaceutical formulation of claim 208.

### Claim 210 (depends on 209)

The method of claim 209, wherein the method results in an insertion or deletion in a gene.

### Claim 211 (depends on 209)

The method of claim 209 further comprising delivering to the cell a template, wherein at least a part of the template incorporates into a target DNA at or near a double strand break site induced by the Cas protein.

### Claim 212 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 129, 130, 131, 132, 133, 134, 135, 136)

The sgRNA of any one of claims 1-78 and 129-136 for use in preparing a medicament for treating a disease or disorder.

### Claim 213 (depends on 163, 737)

The crRNA of any one of claims 737-163 for use in preparing a medicament for treating a disease or disorder.

### Claim 214 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The trRNA of any one of claims 164-189 for use in preparing a medicament for treating a disease or disorder.

### Claim 215 (depends on 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The crRNA of any one of claims 137-163 in combination with the trRNA of any one of claims 164-189 for use in preparing a medicament for treating a disease or disorder.

### Claim 216 (depends on 208)

The pharmaceutical formulation of claim 208 for use in preparing a medicament for treating a disease or disorder.
